Glenmark Life Sciences Ltd. (ALIVUS) Share Price Hits Fresh 52-Week High

Glenmark Life Sciences Ltd. Share Price hits a fresh 52-week high at Rs 1,240, marking a 2.33% rise. Market cap stands at Rs 14,877.44 crore.

Glenmark Life Sciences Ltd. Share Price has reached a fresh 52-week high of Rs 1,240, reflecting a 2.33% increase from the previous close of Rs 1,211.8. This surge in the share price has pushed the company's market capitalisation to Rs 14,877.44 crore. The stock opened at Rs 1,229.95 and fluctuated between a low of Rs 1,205.25 and the new high of Rs 1,240 during the trading session. The turnover for the day was Rs 0.22 crore, with a volume of 1,811 shares traded. This price movement highlights the stock's strong performance in the market.

Glenmark Life Sciences Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,240
Previous Close	Rs 1,211.8
Today's Change	+Rs 28.2 (+2.33%)
Day Open	Rs 1,229.95
Fresh 52-Week High	Rs 1,240
Day Low	Rs 1,205.25
Current Volume	1,811
Turnover	Rs 0.22 crore
Market Capitalisation	Rs 14,877.44 crore

Glenmark Life Sciences Ltd. (ALIVUS) traded at Rs 1,240. versus the previous close of Rs 1,211.8, a rise of 2.33%. The stock opened at Rs 1,229.95, reached Rs 1,240, touched Rs 1,205.25. Reported volume was 1,811.

Today, Glenmark Life Sciences Ltd. Share Price opened at Rs 1,229.95 and quickly climbed to a fresh 52-week high of Rs 1,240. The stock experienced a day low of Rs 1,205.25 before closing at the new high, marking a 2.33% increase from the previous close of Rs 1,211.8. The turnover for the day was Rs 0.22 crore, with a volume of 1,811 shares, indicating moderate trading activity. This upward movement in the share price suggests a positive sentiment among investors.

Glenmark Life Sciences Ltd. (ALIVUS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 14,877.44 crore
P/E Ratio	39.39x
P/B Ratio	7.98x
ROE	28.21%
ROCE	26.35%

Glenmark Life Sciences Ltd. was valued at a P/E ratio of 39.39x, a P/B ratio of 7.98x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	39.39x
Benchmark Median P/E	20.89x
Benchmark Average P/E	73.74x
Benchmark P/E Range	0x to 3,364.06x
Company P/B Ratio	7.98x
Benchmark Median P/B	1.9x
Company ROE	28.21%
Benchmark Median ROE	10.92%
Company ROCE	26.35%
Benchmark Median ROCE	13.29%
Company Market Capitalisation	Rs 14,877.44 crore
Benchmark Median Market Cap	Rs 139.24 crore

Glenmark Life Sciences Ltd. (ALIVUS) is classified under sector: Healthcare.

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 39.39x, which is above the benchmark median of 20.89x, a difference of +88.56%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Glenmark Life Sciences Ltd. (ALIVUS) has a ROE of 28.21%, which is above the benchmark median of 10.92%, a difference of +158.33%. Glenmark Life Sciences Ltd. (ALIVUS) has a ROCE of 26.35%, which is above the benchmark median of 13.29%, a difference of +98.27%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Kwality Pharmaceuticals Ltd.	KPL	2,683.28	39.39	7.98	28.21	26.35
Beta Drugs Ltd.	BETA	2,474.26	62.88	9.95	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,421.1	34.54	6.99	-2.6	16.92
Sai Parenteral's Ltd.	SAIPARENT	2,416.82	171.93	3.18	13.9	12.97
Hester Biosciences Ltd.	HESTERBIO	2,111.45	15.25	4.57	16.17	14.12

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 39.39x compared with the displayed peer median of 39.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 16.17% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Glenmark Life Sciences Ltd. (ALIVUS) has a market capitalisation of Rs 14,877.44 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Glenmark Life Sciences Ltd.

• Glenmark Life Sciences Ltd. Share Price reached a fresh 52-week high, indicating strong market interest.
• The company's valuation metrics suggest a premium position within the sector.
• High ROE and ROCE highlight efficient management and profitability.
• Significant market capitalisation compared to peers.

About Glenmark Life Sciences Ltd.

Glenmark Life Sciences Ltd. is a prominent player in the Healthcare sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs). The company caters to a diverse range of therapeutic segments, including cardiovascular, central nervous system, and dermatology. With a strong emphasis on research and development, Glenmark Life Sciences Ltd. aims to deliver high-quality and cost-effective pharmaceutical solutions. Its robust market presence and strategic partnerships have positioned it as a key player in the pharmaceutical industry.

Track Glenmark Life Sciences Ltd. Share Price on Univest

Use Glenmark Life Sciences Ltd. (ALIVUS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track Glenmark Life Sciences Ltd. Share Price, technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay informed with the latest data and analysis to make well-informed investment decisions.

Frequently Asked Questions

What is the current share price of Glenmark Life Sciences Ltd.?

Ans. The current share price of Glenmark Life Sciences Ltd. is Rs 1,240, marking a fresh 52-week high with a 2.33% increase from the previous close. The stock moved 2.33% during the session.

How does Glenmark Life Sciences Ltd.'s P/E ratio compare to the sector?

Ans. Glenmark Life Sciences Ltd.'s P/E ratio of 39.39 is higher than the sector median of 20.89, indicating a relatively expensive valuation compared to peers. The company trades at a P/E ratio of 39.39x.

What is the market capitalisation of Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. has a market capitalisation of Rs 14,877.44 crore, reflecting its significant size within the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 39.39x.

How does Glenmark Life Sciences Ltd.'s ROE compare to the sector?

Ans. Glenmark Life Sciences Ltd.'s ROE of 28.21% is significantly higher than the sector median of 10.92%, showcasing strong profitability. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.

What is the P/B ratio of Glenmark Life Sciences Ltd.?

Ans. The P/B ratio of Glenmark Life Sciences Ltd. is 7.98, which is above the sector median of 1.9, indicating a premium valuation. The company trades at a P/E ratio of 39.39x.

How does Glenmark Life Sciences Ltd.'s ROCE compare to the sector?

Ans. Glenmark Life Sciences Ltd.'s ROCE of 26.35% is well above the sector median of 13.29%, highlighting efficient capital use. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.

Which peers are compared with Glenmark Life Sciences Ltd.?

Ans. Peers compared include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Dr Agarwals Eye Hospital Ltd., Sai Parenteral's Ltd., and Hester Biosciences Ltd. Comparable listed companies include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Dr Agarwals Eye Hospital Ltd.

What is the significance of Glenmark Life Sciences Ltd.'s 52-week high?

Ans. The 52-week high of Rs 1,240 indicates strong market interest and positive investor sentiment towards Glenmark Life Sciences Ltd. The stock moved 2.33% during the session. The intraday range extended from Rs 1,205.25 to Rs 1,240.